Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;17(12):1020-9.
doi: 10.1007/s12094-015-1455-z. Epub 2015 Dec 21.

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

R García-Campelo  1 , R Bernabé  2 , M Cobo  3 , J Corral  4 , J Coves  5 , M Dómine  6 , E Nadal  7 , D Rodriguez-Abreu  8 , N Viñolas  9 , B Massuti  10
Affiliations

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

R García-Campelo et al. Clin Transl Oncol. 2015 Dec.

Abstract

Lung cancer is the most common cancer worldwide as well as the leading cause of cancer related deaths as reported by Torre et al (CA Cancer J Clin 65:87-108, 2015]. Non-small cell lung cancer (NSCLC) accounts for up to 85 % of all lung cancers. Multiple advances in the staging, diagnostic procedures, therapeutic options, as well as molecular knowledge have been achieved during the past years, although the overall outlook has not greatly changed for the majority of patients with the overall 5-year survival having marginally increased over the last decade from 15.7 to 17.4 % as reported by Howlader et al. (SEER Cancer Statistics Review 2015).

Keywords: Chemotherapy; NSCLC; Radiotherapy; Targeted therapies.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Treatment algorithm for Stage III
Fig. 2
Fig. 2
Treatment algorithm for Stage IV
See this image and copyright information in PMC

References

    1. Torre LA, Bray F, Siegel RL. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi: 10.3322/caac.21262. - DOI - PubMed
    1. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review, 1975–2012. Bethesda: National Cancer Institute; 2015.
    1. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8:823–859. doi: 10.1097/JTO.0b013e318290868f. - DOI - PMC - PubMed
    1. Felip E, Concha A, de Castro J, Gómez-Román J, Garrido P, Ramírez J, et al. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2015;17(2):103–112. doi: 10.1007/s12094-014-1248-9. - DOI - PubMed
    1. Rami-porta R, Crowley JJ, Goldstraw P. The revised TNM system for lung cancer. Ann Thorac Cardiovasc Surg. 2009;15(1):4–9. - PubMed